On 24 January 2013, orphan designation (EU/3/12/1089) was granted by the European Commission to Medical Need Europe AB, Sweden, for choline tetrathiomolybdate for the treatment of Wilson's disease.

The sponsorship was transferred to Wilson Therapeutics AB, Sweden, in July 2014.

The sponsorship was transferred to Alexion Europe S.A.S., France, in February 2019.

Key facts

Active substance
Choline tetrathiomolybdate
Disease / condition
Treatment of Wilson's disease
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Alexion Europe S.A.S.
1-15 Avenue Edouard Belin
92500 Rueil-Malmaison
Tel.  +33 1471 00615

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating